Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Phase II Study of Tislelizumab Combined with Chemotherapy in Triple Negative Breast Cancer
ChiCTR2000035262Phase 2Not yet recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in triple-negative breast cancer (TNBC), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Pathological complete response. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2000035262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035262.